Takahiro Nakayama

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 6

Top Topics

Metastatic Breast Cancer

Radiation Therapy

Systematic Review

Top Venues

Breast cancer (Tokyo, Japan)

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Hiroki Kusama, Nobuyoshi Kittaka, Ai Soma, Azusa Taniguchi, Haruka Kanaoka, Satomi Nakajima, Yuri Oyama, Yukiko Seto, Jun Okuno, Noriyuki Watanabe, Saki Matsui, Minako Nishio, Fumie Fujisawa, Keiichirou Honma, Yasuhiro Tamaki, Takahiro Nakayama
Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer. Breast cancer (Tokyo, Japan) (2023)
Manabu Futamura, Takahiro Nakayama, Tetsuhiro Yoshinami, Chiya Oshiro, Mikiya Ishihara, Midori Morita, Akira Watanabe, Azusa Tanigichi, Masami Tsukabe, Masafumi Shimoda, Kanae Nitta, Yoko Chihara, Hiroyuki Yasojima, Yoshimi Ouchi, Yoshihisa Tokumaru, Norikazu Masuda
Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316). Breast cancer (Tokyo, Japan) (2023)
Mizuki Kato, Kayo Nakata, Toshitaka Morishima, Yoshihiro Kuwabara, Fumie Fujisawa, Nobuyoshi Kittaka, Takahiro Nakayama, Isao Miyashiro
Fifteen-year survival and conditional survival of women with breast cancer in Osaka, Japan: A population-based study. Cancer medicine (2023)
Norikazu Masuda, Tetsuhiro Yoshinami, Masahiko Ikeda, Makiko Mizutani, Miki Yamaguchi, Yoshifumi Komoike, Tsutomu Takashima, Katsuhide Yoshidome, Junji Tsurutani, Mitsuhiko Iwamoto, Fumie Fujisawa, Hiroyuki Yasojima, Jun Yamamura, Hirotaka Morishima, Fuminori Aki, Tomomi Yamada, Satoshi Morita, Takahiro Nakayama
Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214. Cancers 13 (17) (2021)
Takahiro Nakayama, Tetsuhiro Yoshinami, Hiroyuki Yasojima, Nobuyoshi Kittaka, Masato Takahashi, Shoichiro Ohtani, Seung Jin Kim, Hiroyuki Kurakami, Naoko Yamamoto, Tomomi Yamada, Takehiko Takata, Norikazu Masuda
Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917). BMC cancer 21 (1) (2021)
Takahiro Nakayama, Fumie Fujisawa
Therapy options after CDK4/6 inhibitors for HR+, HER2- postmenopausal metastatic/recurrent breast cancer in Japan: a role for mammalian target of rapamycin inhibitors? Future oncology (London, England) 16 (24) (2020)